Study on Diagnosis Value of mNGS Technology Among Diabetic Patients With Pulmonary Infections

Launched by RUIJIN HOSPITAL · Sep 22, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a special testing technology called mNGS (metagenomic next-generation sequencing) can help diagnose lung infections in patients with diabetes. The study aims to understand how common these infections are, what causes them, and how they are being treated. It will also explore how the lungs and the body's immune system respond to these infections in people with diabetes, with the goal of improving clinical care.

To be part of this trial, participants need to be at least 18 years old and have been diagnosed with a lung infection through tests like X-rays or CT scans, which show specific signs of infection. The study is currently recruiting and is open to everyone, regardless of gender. If you join the trial, you can expect to provide information about your health and undergo some tests related to your condition. It’s important to note that if someone stops coming to appointments or decides not to participate anymore, they will not be able to continue in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis by pathogen examination: positive
• • Diagnosis through X-ray or CT: characteristic features of pulmonary infection
• • Age older than 18 years
• Exclusion Criteria:
• • Irregular follow-up and lost follow-up
• • Withdraw from the study for any reason